HEREDITARY CYSTATIN C AMYLOID ANGIOPATHY (HCCAA)

Clinical trials for HEREDITARY CYSTATIN C AMYLOID ANGIOPATHY (HCCAA) explained in plain language.

Never miss a new study

Get alerted when new HEREDITARY CYSTATIN C AMYLOID ANGIOPATHY (HCCAA) trials appear

Sign up with your email to follow new studies for HEREDITARY CYSTATIN C AMYLOID ANGIOPATHY (HCCAA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Experimental drug aims to curb brain bleeds in rare genetic disease

Disease control Ongoing

This study tests an experimental drug, NPI-001 (AT-001), in people with hereditary cystatin C amyloid angiopathy (HCCAA), a rare genetic condition that causes repeated brain bleeding and stroke. The trial includes about 15 participants aged 12 and older who carry the specific L68…

Matched conditions: HEREDITARY CYSTATIN C AMYLOID ANGIOPATHY (HCCAA)

Phase: PHASE2 • Sponsor: Arctic Therapeutics • Aim: Disease control

Last updated Jul 23, 2026 00:00 UTC

HEREDITARY CYSTATIN C AMYLOID ANGIOPATHY (HCCAA)

Get alerted when new HEREDITARY CYSTATIN C AMYLOID ANGIOPATHY (HCCAA) trials appear

Experimental drug aims to curb brain bleeds in rare genetic disease